Immunoglobulines humaines produites par voie de génie génétique

Human immunoglobulines produced by recombinant DNA techniques

Durch rekombinante DNA-Technik hergestellte menschliche Immunglobuline

Abstract

Recombinant human immunoglobulins and methods for their production are provided. DNA constructs containing operably linked genes coding for human light and heavy chains are transfected into eucaryotic host cells capable of expressing the human immunoglobulin sequences. Using these methods the isotype of an immunoglobulin may be switched, or a monoclonal antibody may be produced in a new host cell free of a transforming virus' genome. Also disclosed is the use of cytomegalovirus transcriptional enhancer sequences to increase expression of immunoglobulin genes. The recombinant immunoglobulins find use in a number of ways, including prophylaxis and therapy, diagnosis, and as immunogens.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (3)

    Title
    JOURNAL OF IMMUNOLOGICAL METHODS, vol. 100, nos. 1/2, 1987,pages 5-40, Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, NL; K. JAMES et al.: "Human monoclonal antibody production. Current status and future prospects"
    NATURE, vol. 321, 29th May 1986, pages 522-525; P.T. JONES et al.: "Replacing the complementarity-determining regions in a human antibody with those from a mouse"
    NUCLEIC ACIDS RESEARCH, vol. 12, no. 22, November 1984, pages 8407-8414, IRL Press Ltd, Cambridge, GB; Y. TSUJIMOTO et al.: "Molecular cloning of a human immunoglobulin gamma chain variable sequence"

Cited By (89)

    Publication numberPublication dateAssigneeTitle
    US-5866692-AFebruary 02, 1999Kyowa Hakko Kogyo Co., Ltd.Process for producing humanized chimera antibody
    US-8298538-B2October 30, 2012Institute For Research In BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
    US-5750078-AMay 12, 1998Kyowa Hakko Kogyo Co., Ltd.Process for producing humanized chimera antibody
    US-5610034-AMarch 11, 1997Alko Group Ltd.Immunoglobulin production by trichoderma
    US-5807548-ASeptember 15, 1998Kyowa Hakko Kogyo Co., Ltd.Method of treating cancer using a chimera antibody
    WO-9201797-A1February 06, 1992Oy Alko AbIMMUNOGLOBULIN PRODUCTION BY $i(TRICHODERMA)
    EP-2314629-A1April 27, 2011Merus B.V.Rekombinante Herstellung von Mischungen aus Aantikörpern
    US-8765132-B2July 01, 2014Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-9023361-B2May 05, 2015Kyowa Hakko Kirin Co., Ltd.Methods for treating transplant rejection by administering anti-CD40 antibody
    US-7981419-B2July 19, 2011Kyowa Hakko Kirin Co., Ltd.Method for treating hypophosphatemic bone diseases using FGF-23 antibody
    US-5830470-ANovember 03, 1998Kyowa Hakko Kogyo Co., Ltd.Humanized antibodies to ganglioside GM2
    US-7923012-B2April 12, 2011Kyowa Hakko Kirin Co., Ltd.Antibody against fibroblast growth factor-23
    US-9527902-B2December 27, 2016Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    WO-2008099969-A1August 21, 2008Kyowa Hakko Kirin Co., Ltd.抗fgf23抗体及びそれを含む医薬組成物
    US-7145056-B2December 05, 2006Abgenix, Inc., Japan Tobacco, Inc.Production of antibodies using cre-mediated site-specific recombination
    US-6495666-B2December 17, 2002Kyowa Hakko Kogyo Co., Ltd.Polypeptide composing human chimeric antibody
    US-9221897-B2December 29, 2015Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-9303081-B2April 05, 2016Merus B.V.Recombinant production of mixtures of antibodies
    US-6872392-B2March 29, 2005Kyowa Hakko Kogyo Co., Ltd.Humanized antibodies
    US-8568725-B2October 29, 2013Kyowa Hakko Kirin Co., Ltd.Method of treating transplant rejection with an anti-CD40 antibody
    US-9796771-B2October 24, 2017Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-9149524-B2October 06, 2015Institute For Research In BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
    US-6965024-B2November 15, 2005Kyowa Hakko Kogyo Co., Ltd.Process for producing humanized chimera antibody
    US-9796772-B2October 24, 2017Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-7919257-B2April 05, 2011Merus Biopharmaceuticals, B.V.I.O.Method for selecting a single cell expressing a heterogeneous combination of antibodies
    WO-2013157954-A1October 24, 2013Merus B.V.Methods and means for the production of ig-like molecules
    US-7927834-B2April 19, 2011Merus B.V.Recombinant production of mixtures of antibodies
    US-RE39792-EAugust 21, 2007Smithkline Beecham CorporationMethod for culturing Chinese hamster ovary cells
    US-9611316-B2April 04, 2017Institute For Research In BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
    US-5876961-AMarch 02, 1999Glaxo Wellcome Inc.Production of antibodies
    US-9290569-B2March 22, 2016Kyowa Hakko Kirin Co., Ltd.Anti FGF23 antibody and a pharmaceutical composition comprising the same
    EP-2527437-A1November 28, 2012Kyowa Hakko Kirin Co., Ltd.Novel anti-CD98 antibody
    EP-0462246-A1December 27, 1991Bristol-Myers Squibb CompanyImmunoglobulines oligomeres
    US-8545848-B2October 01, 2013Institute For Research In BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
    US-9777290-B2October 03, 2017Lonza Biologics PlcExpression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
    US-7429486-B2September 30, 2008Crucell Holland B.V.Recombinant production of mixtures of antibodies
    US-8603480-B2December 10, 2013Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-8124093-B2February 28, 2012Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-9365636-B1June 14, 2016Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-7045129-B2May 16, 2006Kyowa Hakko Kogyo Co., Ltd.Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3
    WO-2013157953-A1October 24, 2013Merus B.V.Methods and means for the production of ig-like molecules
    US-8298539-B2October 30, 2012Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    WO-2004009618-A2January 29, 2004Crucell Holland B.V.Production par recombinaison de melanges d'anticorps
    US-8435524-B2May 07, 2013Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-9725502-B2August 08, 2017Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-9371372-B2June 21, 2016Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    WO-2007114496-A1October 11, 2007Kirin Pharma Kabushiki Kaisha新規抗cd98抗体
    US-RE41974-ENovember 30, 2010Glaxosmithkline LlcMethod for culturing Chinese hamster ovary cells
    US-8309089-B2November 13, 2012Institute For Research In BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
    EP-0462246-A4November 25, 1992Bristol-Myers Squibb CompanyOligomeric immunoglobulins
    US-9249213-B2February 02, 2016Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-9491906-B2November 15, 2016Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    EP-2711426-B1April 08, 2015Lonza Biologics plcExpressionsvektoren mit chimärem Cytomegalieviruspromotor und Verstärkersequenzen
    US-6437098-B1August 20, 2002Kyowa Hakko Kogyo Co., Ltd.Human chimeric antibody specific for the ganglioside GD3
    EP-0817835-A4January 05, 2005Abgenix Inc, Japan Tobacco IncHerstellung von antikörpern mittels cre-vermittelter ortsspezifischer rekombination
    US-5939532-AAugust 17, 1999Kyowa Hakko Kogyo Co., LtdHumanized antibodies to ganglioside GM2
    WO-9302190-A1February 04, 1993The Wellcome Foundation LimitedProduction of antibodies
    EP-2145954-A1January 20, 2010Kyowa Hakko Kirin Co., Ltd.Anticorps anti-A33
    EP-0598998-A2June 01, 1994Kyowa Hakko Kogyo Co., LtdAnticorps humanisés réagissant avec le ganglioside GM2
    US-9023360-B2May 05, 2015Kyowa Hakko Kirin Co., Ltd.Methods of treating autoimmune disease with anti-CD40 antibodies
    US-9217028-B2December 22, 2015Institute For Research In BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
    US-9758805-B2September 12, 2017Merus N.V.Methods and means for the production of Ig-like molecules
    EP-2011802-A2January 07, 2009Kirin Pharma Kabushiki KaishaAnticorps monoclonal anti-CD40
    EP-2502996-A2September 26, 2012Kyowa Hakko Kirin Co., Ltd.Anti-FGF23-Antikörper und pharmazeutische Zusammensetzung damit
    EP-0533199-A2March 24, 1993Kyowa Hakko Kogyo Co., Ltd.Procédé de production d'anticorps chimères "humanisés". Application à un anticorps chimérique dirigé contre le ganglioside GD3
    US-7955599-B2June 07, 2011Humabs, LLCHuman cytomegalovirus neutralizing antibodies and use thereof
    US-6423511-B1July 23, 2002Kyowa Hakko Kogyo Co., Ltd.Humanized antibodies
    US-8287870-B2October 16, 2012Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-9012371-B2April 21, 2015Merus B.V.Mixtures of binding proteins
    US-9738701-B2August 22, 2017Merus N.V.Method for selecting a single cell expressing a heterogeneous combination of antibodies
    EP-0533199-A3October 06, 1993Kyowa Hakko Kogyo Co., Ltd.Application to a chimeric antibody directed against ganglioside gd3
    US-9127049-B2September 08, 2015Institute For Research In BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    EP-0523949-A1January 20, 1993The Wellcome Foundation LimitedProduction of antibodies
    EP-0270077-A3September 06, 1989Sumitomo Chemical Company, Limited, Sumitomo Pharmaceuticals Company, LimitedAntibody to exotoxin of pseudomonas aeruginosa and gene therefor
    US-7883705-B2February 08, 2011Kyowa Hakko Kirin Co., Ltd.Anti FGF23 antibody and a pharmaceutical composition comprising the same
    US-8268756-B2September 18, 2012Merus B.V.Mixture of binding proteins
    WO-2007108559-A1September 27, 2007Kirin Pharma Kabushiki KaishaAgonistic antibody directed against human thrombopoietin receptor
    CN-104718296-AJune 17, 2015英国龙沙生物医药股份有限公司Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
    WO-9104336-A1April 04, 1991Centocor, Inc.Method for improving human monoclonal antibody production
    WO-2014044845-A1March 27, 2014Lonza Biologics Plc.Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
    US-7932360-B2April 26, 2011Merus B.V.Recombinant production of mixtures of antibodies
    EP-0817835-A1January 14, 1998Xenotech IncorporatedProduction d'anticorps par recombinaison specifique a un site induite par la recombinase cre
    US-9803000-B1October 31, 2017Institute of Research in BiomedicineHuman cytomegalovirus neutralizing antibodies and use thereof
    US-7947274-B2May 24, 2011Humabs, LLC.Human cytomegalovirus neutralising antibodies and use thereof
    EP-0598998-A3January 22, 1997Kyowa Hakko Kogyo KkAnticorps humanisés réagissant avec le ganglioside GM2.
    EP-0270077-A2June 08, 1988Sumitomo Chemical Company, Limited, Sumitomo Pharmaceuticals Company, LimitedAnticorps contre une exotoxine de pseudomonas aeruginosa ainsi que gène à cet effet
    US-7262028-B2August 28, 2007Crucell Holland B.V.Recombinant production of mixtures of antibodies
    EP-2009027-A1December 31, 2008Kirin Pharma Kabushiki KaishaMonoklonaler Antikörper gegen CD40
    EP-3181691-A1June 21, 2017Kyowa Hakko Kirin Co., Ltd.Anticorps anti-fgf23 et composition pharmaceutique le comprenant